Aug 2026· Experimental Eye Research· pp.
111215
· 0 citations· 48 references
Medicine
TL;DR
Overall, this study suggests that viral or pharmacological approaches activating the TFEB pathway in the RPE could be beneficial as cell-protective treatment of early/intermediate cases of AMD, acting to delay progression of the disease.
Abstract
Age-related macular degeneration (AMD) is the most common blinding disease in the western world and is currently incurable. Although the exact causes of AMD are not clear, the primary origin of pathology appears to be the aged retinal pigment epithelium (RPE) exhibiting signs of lysosomal dysfunction and oxidative damage. RPE is responsible for the daily digestion of photoreceptor outer segments (POS), imposing a heavy continuous burden on the lysosomal network. A cellular model of RPE lysosomal dysfunction can be achieved by feeding RPE with a single pulse of POS, leading to the accumulation of autofluorescence granules (AFG), similar to lipofuscin in vivo. Here we show that synchronous phagocytosis of POS leads to early transient mTOR activation followed by inhibition in late phagosome maturation. One of its substrates, the transcription factor EB (TFEB) increases during phagosome maturation albeit mostly in its inactive phosphorylated form. We questioned whether modulation of the mTOR/TFEB axis could improve POS clearance and hence reduce AFG load. Treatment of POS-fed cells after the appearance of AFGs with rapamycin, an mTORC1 inhibitor results in ∼30% reduction of AFG load. This effect is dependent on active lysosomal enzymes and induction of active dephosphorylated TFEB with consequent activation of GADD34 and lysosomal biogenesis. As a proof of concept, we show that overexpressing a constitutively active form of unphosphorylated TFEB dramatically reduces POS-dependent AFG accumulation. Overall, this study suggests that viral or pharmacological approaches activating the TFEB pathway in the RPE could be beneficial as cell-protective treatment of early/intermediate cases of AMD, acting to delay progression of the disease.
ADORA2A activation promotes Rubicon-associated, lysosome-dependent LC3 processing of internalized POS and restores lysosomal degradative competence, supporting ADORA2A as a potential therapeutic target for early AMD.
D. Tao, Daiyi Zhou, Ming-Juan Wu et al.· Frontiers in Physiology· 0 citations
Age-related macular degeneration (AMD) is a fundus oculi disease that progressively impairs the central vision of patients. To date, its pathogenesis has not been fully elucidated, and therapeutic options for dry AMD remain limited. Recently, chronic low-grade inflammation has been recognized as an important pathogenic...
Meijiao Zhu, Weihong Yu· Frontiers in Aging Neuroscie...· 0 citations
A peripheral RPE subpopulation is identified through spatial, transcriptomic, and functional analyses, thereby contributing to the understanding of the heterogeneity of degenerative RPE cells and highlighting SERPINE3 as a protective factor with therapeutic potential for macular atrophy.
Hui-Rong Li, Takerra K. Johnson-Stephenson, Vincent P. Kunze et al.· Journal of Clinical Investig...· 0 citations
It is reported that CCR1 is expressed in Müller glia in eyes affected by AMD and that variants in CCR1 are potentially associated with the rate of macular atrophy progression in AMD, and that CCR1 may serve as a novel therapeutic target for atrophic AMD and IRDs.
Sarah Elbaz-Hayoun, Lian Omari, Shlomit Jaskoll et al.· Journal of Neuroinflammation· 0 citations
Induced pluripotent stem cell–derived retinal pigment epithelial cells from a patient with MAL showed therapeutic potential for MAL and other drusen-related diseases, including age-related macular degeneration, and pharmacological restoration of lysosomal function alleviated defects.
Yumi Inoue, H. Ikeda, Masayuki Hata et al.· JCI Insight· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.